Literature DB >> 9448590

Treatment of good-prognosis polyarteritis nodosa and Churg-Strauss syndrome: comparison of steroids and oral or pulse cyclophosphamide in 25 patients. French Cooperative Study Group for Vasculitides.

M Gayraud1, L Guillevin, P Cohen, F Lhote, P Cacoub, P Deblois, B Godeau, M Ruel, E Vidal, M Piontud, J P Ducroix, S Lassoued, B Christoforov, P Babinet.   

Abstract

Twenty-five patients with good-prognosis polyarteritis nodosa or Churg-Strauss syndrome entered a prospective, randomized, multicentre study comparing two treatments: either oral corticosteroids and oral cyclophosphamide (CY; 2 mg/kg/day) for 1 yr (group A), or oral corticosteroids and monthly i.v. CY pulses (0.6 g/m2) (group B) for 1 yr. The objective was to determine the optimal CY regimen. Judgement criteria were the efficacy of the treatment in controlling the disease and the development of side-effects. Among the 25 patients who could be analysed, complete recovery was achieved with the experimental treatment in 9/12 patients in group A and 10/13 patients in group B. Two patients in each group relapsed after the end of therapy and were well controlled by corticosteroids or other drugs. One failure occurred in each group. The mean follow-up was 60.8 +/- 14.5 months after the beginning of the treatment. Side-effects associated with the administration of CY and steroids were noted 27 times in group A vs 14 times in group B (not significant). The oldest patient in these series (group B) died of pneumonia. No superiority in terms of efficacy could be established between the two regimens; however, the number of patients included was too small to conclude definitively. Toxic side-effects were significantly more frequent in women (P < 0.02). The high number of adverse effects leads us to recommend pulse over oral CY and an overall lowering of the doses of immunosuppression.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9448590     DOI: 10.1093/rheumatology/36.12.1290

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  30 in total

Review 1.  Wegener's granulomatosis and the Churg-Strauss syndrome.

Authors:  J L Faul; W G Kuschner
Journal:  Clin Rev Allergy Immunol       Date:  2001-08       Impact factor: 8.667

Review 2.  Clinical management and treatment of vasculitis.

Authors:  D Jayne
Journal:  Springer Semin Immunopathol       Date:  2001

3.  [Polyarteritis nodosa: differential diagnostics and therapy].

Authors:  J H Schirmer; K Holl-Ulrich; F Moosig
Journal:  Z Rheumatol       Date:  2014-12       Impact factor: 1.372

4.  Systemic vasculitis presenting with acute gastrointestinal hemorrhage: case report and review of the literature.

Authors:  Chad M Sisk; Chris Parker; Tim Cassidy; Allan Parker
Journal:  Dig Dis Sci       Date:  2003-09       Impact factor: 3.199

Review 5.  [Therapy of primary systemic vasculitis].

Authors:  K de Groot; W L Gross; B Hellmich
Journal:  Internist (Berl)       Date:  2003-12       Impact factor: 0.743

Review 6.  EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis.

Authors:  Bernhard Hellmich; Oliver Flossmann; Wolfgang L Gross; Paul Bacon; Jan Willem Cohen-Tervaert; Loic Guillevin; David Jayne; Alfred Mahr; Peter A Merkel; Heiner Raspe; David G I Scott; James Witter; Hasan Yazici; Raashid A Luqmani
Journal:  Ann Rheum Dis       Date:  2006-12-14       Impact factor: 19.103

7.  Rituximab in Churg-Strauss syndrome.

Authors:  M Koukoulaki; K G C Smith; D R W Jayne
Journal:  Ann Rheum Dis       Date:  2006-04       Impact factor: 19.103

Review 8.  Pulmonary vasculitis.

Authors:  Kevin K Brown
Journal:  Proc Am Thorac Soc       Date:  2006

Review 9.  Eosinophilic pneumonias.

Authors:  Praveen Akuthota; Peter F Weller
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

Review 10.  Cyclophosphamide treatment in systemic necrotizing vasculitis and lupus nephritis. How long? How much?

Authors:  J H M Beimler; K Andrassy
Journal:  Pediatr Nephrol       Date:  2004-07-15       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.